Products
Data
Feature
Plans
Request Demo
Sign Up for Free
Blog
Valuable Targets
Advanced Tech.
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
NCT07714447 ARM-002TM KRAS G12D mutation Colorectal cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07714447 clinical trial report covering ARM-002TM, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
Latest Hotspot
8 min read
NCT07715318 Spironolactone Anemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07715318 clinical trial report covering Spironolactone, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
Latest Hotspot
8 min read
NCT07714551 Zanzalintinib Pheochromocytoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07714551 clinical trial report covering Zanzalintinib, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
Latest Hotspot
8 min read
NCT07712926 Tetravalent dengue virus vaccine(Instituto Butantan) Dengue Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07712926 clinical trial report covering Tetravalent dengue virus vaccine(Instituto Butantan), Phase 3, endpoints, sponsor, geography, readout timing and de
Read →
Latest Hotspot
8 min read
NCT07714616 Cyproterone Acetate Contraception Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07714616 clinical trial report covering Cyproterone Acetate, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
Latest Hotspot
8 min read
SillaJen Company BD Opportunity Scan Report 2026: Pipeline, Deals, Partnering Shortlist, and Outreach Priorities
21 July 2026
SillaJen 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.
Read →
Latest Hotspot
8 min read
Genexine Company BD Opportunity Scan Report 2026: Pipeline, Deals, Partnering Shortlist, and Outreach Priorities
21 July 2026
Genexine 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.
Read →
Latest Hotspot
8 min read
Ractigen Therapeutics Company BD Opportunity Scan Report 2026: Pipeline, Deals, Partnering Shortlist, and Outreach Priorities
21 July 2026
Ractigen Therapeutics 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.
Read →
Latest Hotspot
8 min read
Sirnaomics Company BD Opportunity Scan Report 2026: Pipeline, Deals, Partnering Shortlist, and Outreach Priorities
21 July 2026
Sirnaomics 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.
Read →
Latest Hotspot
8 min read
Suzhou Ribo Life Science Company BD Opportunity Scan Report 2026: Pipeline, Deals, Partnering Shortlist, and Outreach Priorities
21 July 2026
Suzhou Ribo Life Science 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.
Read →
Latest Hotspot
8 min read
Stemirna Therapeutics Company BD Opportunity Scan Report 2026: Pipeline, Deals, Partnering Shortlist, and Outreach Priorities
21 July 2026
Stemirna Therapeutics 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.
Read →
Latest Hotspot
8 min read
Immorna Biotherapeutics Company BD Opportunity Scan Report 2026: Pipeline, Deals, Partnering Shortlist, and Outreach Priorities
21 July 2026
Immorna Biotherapeutics 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.
Read →
<
1
<<
1397
1398
1399
1400
1401
>>
2135
>